Central Laboratories Featured Articles

1. Reimagining Data Governance For The AI Era 4/24/2026

   Understand the persistent governance challenges that undermine AI initiatives and walk away with a robust blueprint for building a resilient, scalable, and ethically sound framework.

2. Is It Time To Replace RECIST — Or Just Add AI? 4/16/2026

   Immunocore Chief Regulatory and Quality Officer Mark Moyer explains why new tools, including AI-based approaches, may better capture cancer treatment response than existing measures, such as ir-RECIST.

3. RBQM And Centralized Monitoring Need Action 4/10/2026

   After COVID forced sponsors to move faster than ever, many are now confronting a harder challenge: ownership. Marci Thear explains why RBQM and centralized monitoring only work when sponsors move beyond reviewing outputs and start acting on the signals.

4. Redefining Patient Outcomes Measurement Using RWE Data 4/7/2026

   Discover an outcome-channeling framework that organizes patient outcomes into multidimensional domains, emphasing longitudinal trajectories rather than single time endpoints.

5. RWD Helps Researchers Include More Patients In Lymphoma Research 4/2/2026

   Andrew Evens, DO, MBA, explores how outcomes research and collaboration across academic networks, registries, and industry partners are advancing more inclusive, data-informed approaches to lymphoma research.

6. Unlocking Biopharma Innovation With Real-World Evidence 3/30/2026

   Discover how how federated data networks, platform aggregators, and collaborative partnerships have evolved to meet the data demands of modern product development, regulatory strategy, and commercial success.

7. Bayesian Digital Twins Show Potential For Predicting Prognosis And Treatment Response 3/30/2026

   Learn how Bayesian digital twins are trained, validated, and trusted in clinical settings and explore the potential for integrating these models into interventional trials.

8. From Real-World Data To Real-World Impact: Building The Evidence Capability Pharma Actually Needs 3/25/2026

   Learn how companies that treat RWE as an operational capability will be better positioned to design more efficient trials, accelerate therapy adoption, strengthen payer negotiations, and demonstrate value across the healthcare ecosystem.

9. A Clinical Machine Learning Operations (MLOps) Maturity Framework For Biopharma 3/24/2026

   Pharma has invested substantially in machine learning applications, but investment in the operational infrastructure — the MLOps layer — has lagged. The time to build that infrastructure is now — not after your next trial fails.

10. Don't Let The Nocebo Effect In Psychedelic Trials Become A Regulatory Problem 3/23/2026

    When a patient feels no effect or a worsening effect because a known treatment effect was or wasn't experience, that's the "nocebo" effect. Strategic Advisor Jama Pittman discusses how this effect could impact regulatory reviews.